Benzinga's Small Cap Movers for Thursday February 21, 2013
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of CombiMatrix (NASDAQ: CBMX), the Irvine, CA molecular diagnostics company, rose 136% Thursday on 6.5 times average volume.
A Seeking Alpha report on Thursday said CombiMatrix sheares would double by the end of February. And today they did, trading as high as $7.64.
CombiMatrix closed at $6.75 on Thursday.
ParkerVision (NASDAQ: PRKR), the Jacksonville, CA designer, developer and marketer of proprietary RF technologies, rose 73% Thursday on 33 times average volume.
ParkerVision announced Thursday that on February 20, 2013, the United States District Court for the Middle District of Florida issued its patent claim construction ruling, or "Markman Order", in the ongoing patent infringement action between ParkerVision and Qualcomm (NASDAQ: QCOM). The litigation, filed in July 2011, involves Qualcomm's development and sale of certain of its products that ParkerVision believes infringe numerous claims from six patents owned by ParkerVision.
ParkerVision closed at $4.21 on Thursday.
Shares of NeuroMetrix (NASDAQ: NURO), the Waltham, MA medical device company, rose 29% Thursday on 21 times average volume.
NeuroMetrix share rose on chatter of a potential deal or collaboration with Amgen (NASDAQ: AMGN).
A spokesperson for Amgen declined comment on the rumor. A NeuroMetrix spokesperson was not available for comment.
NeuroMetrix closed at $3.00 on Thursday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.